Systemic Lupus Clinical Trial
Official title:
Role of Online Hemodiafiltration With Endogenous Reinfusion in Treatment of Systemic Lupus Erythematosus Activity Resistant to Conventional Therapy
Background: lupus is a heterogeneous autoimmune disease with autoantibodies formation. Lupus nephritis carries the worst prognosis. C1q deficiency correlates with activity and renal involvement and may help in its evaluation. Therapies include plasma exchange, immune adsorption and recently under evaluation, hemodiafiltration with on-line endogenous re infusion (HFR), in addition to traditional immunosuppressive therapies. Aim: is to evaluate the role of HFR in improving signs and symptoms of SLE activity and laboratory parameters not responding to traditional immune suppressive therapy
Settings and design: A controlled clinical study was conducted on group A, sixty patients
with lupus in activity subdivided into cases 1, 47 patients, who received traditional medical
treatment and cases 2 group, 13 patients, who underwent HFR in addition to medical treatment.
And group B that consisted of two subgroups, control 1, 20 healthy age and sex matched
volunteers and control 2, 10 cases with different glomerular diseases other than lupus.
Methods and materials: Serum c1q was done before and after the HFR as well as induction by
medical treatment. Disease activity assessed using SLEDAI-2K with responder index - 50,
quality of life assessed using SLEQOL v2, and HFR was performed for the non-responder group.
The study will be conducted in Alexandria University Hospitals in compliance with the
Declaration of Helsinki; the ethical committee of the investigator's faculty will be
requested to approve the protocol and the patients will be requested to give informed
consent.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03749044 -
ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies
|
N/A | |
| Completed |
NCT03218033 -
Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus
|
N/A | |
| Not yet recruiting |
NCT03752983 -
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
|
||
| Recruiting |
NCT03819777 -
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
|
||
| Recruiting |
NCT04894253 -
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
|
||
| Not yet recruiting |
NCT03164720 -
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
|
||
| Completed |
NCT03762824 -
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
|
Phase 4 | |
| Terminated |
NCT01738360 -
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
|
Phase 2 | |
| Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
| Not yet recruiting |
NCT04256577 -
Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
|
||
| Completed |
NCT03540823 -
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
|
Phase 4 |